Abstract: The controller of a wearable device is used to determine swim characteristics of a swimmer. The controller is connected to at least one motion sensor selected from a group including a multi-axis gyroscope and a multi-axis accelerometer. The controller is adapted to detect input signals from the at least one motion sensor. The controller is further configured to perform dynamic stroke segmentations based on at least one of the input signals using a stroke segmentation module, extract feature vectors, using feature extraction module, from the at least one input signal based on the stroke segmentations, and determine the swim characteristics by using the feature vectors through a classifier module. The controller dynamically adapts to a style of the swimmer to detect the swim characteristics.

Abstract: A system for providing navigation services to a user in a volume of space can include a user device disposed in the volume of space, where the user device broadcasts, at a first time, at least one first communication signal into the volume of space, where the at least one first communication signal includes a first identification of the user and a destination of the user. The system can also include multiple electrical devices disposed in the volume of space, where each electrical device includes a transceiver, where the transceiver of a first subset of the electrical devices receives the at least one first communication signal broadcast by the user device, where the first subset of electrical devices sends a second communication signal based on the at least one first communication signal. The system can further include a controller communicably coupled to the plurality of electrical devices.

Abstract: A system for providing navigation services to a user in a volume of space can include a user device disposed in the volume of space, where the user device broadcasts, at a first time, at least one first communication signal into the volume of space, where the at least one first communication signal includes a first identification of the user and a destination of the user. The system can also include multiple electrical devices disposed in the volume of space, where each electrical device includes a transceiver, where the transceiver of a first subset of the electrical devices receives the at least one first communication signal broadcast by the user device, where the first subset of electrical devices sends a second communication signal based on the at least one first communication signal. The system can further include a controller communicably coupled to the plurality of electrical devices.

Abstract: This invention provides CCI-779 cosolvent concentrates which are useful in preparing a parenteral formulation of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779) following admixture with a diluent.

Abstract: This invention provides CCI-779 cosolvent concentrates which are useful in preparing a parenteral formulation of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779) following admixture with a diluent.

Abstract: This invention provides CCI-779 cosolvent concentrates which are useful in preparing a parenteral formulation of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779) following admixture with a diluent.

Abstract: This invention provides CCI-779 cosolvent concentrates which are useful in preparing a parenteral formulation of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779) following admixture with a diluent.

Abstract: This invention provides CCI-779 cosolvent concentrates which are useful in preparing a parenteral formulation of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779) following admixture with a diluent.

Abstract: Parenteral formulations of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl) -2-methylpropionic acid (CCI-779) are provided. One parenteral formulation contains CCI-779, an alcoholic co-solvent, and an antioxidant. Another parenteral formulation contains CCI-779, an alcoholic solvent, an antioxidant, a diluent solvent, and a surfactant. Processes for preparing parenteral CCI-779 formulations using a co-solvent concentrate are also provided.

Abstract: A method of preparing a rapamycin composition having increased potency is provided. The method involves selecting a rapamycin compound having less than 1.5% oxidative and hydrolytic rapamycin impurities and formulating the selected rapamycin with an antioxidant and optional excipients.

Abstract: The present disclosure is directed to combination therapies of tigecycline and heparin and methods of administration of tigecycline and heparin.

Abstract: This invention provides parenteral formulations of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779).